Stakeholders' views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology.
- Publisher:
- Springer Science and Business Media LLC
- Publication Type:
- Journal Article
- Citation:
- Eur J Hum Genet, 2021, 29, (11), pp. 1634-1644
- Issue Date:
- 2021-11
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
19178675_8151771760005671.pdf | Published version | 1.79 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | O'Shea, R | |
dc.contributor.author | Rankin, NM | |
dc.contributor.author | Kentwell, M | |
dc.contributor.author | Gleeson, M | |
dc.contributor.author | Tucker, KM | |
dc.contributor.author | Hampel, H | |
dc.contributor.author | Taylor, N | |
dc.contributor.author | Lewis, S | |
dc.date.accessioned | 2022-06-15T23:29:35Z | |
dc.date.available | 2021-03-11 | |
dc.date.available | 2022-06-15T23:29:35Z | |
dc.date.issued | 2021-11 | |
dc.identifier.citation | Eur J Hum Genet, 2021, 29, (11), pp. 1634-1644 | |
dc.identifier.issn | 1018-4813 | |
dc.identifier.issn | 1476-5438 | |
dc.identifier.uri | http://hdl.handle.net/10453/158200 | |
dc.description.abstract | Mainstream genetic testing in routine oncology care requires implementation research to inform intervention design. In Australia, funding is available for oncology health professionals (OHP) to organise genetic testing (GT) for eligible colorectal and endometrial cancer patients as part of their routine care. To assess the health system ability to incorporate this practice change, we conducted an implementation survey using the Consolidated Framework for Implementation Research (CFIR). The online survey was available from April to September 2020 to OHP and genetic health professional (GHP). In total, 198 respondents attempted the survey, with 158 completed and 27 partial responses: 26% were GHP, 66% OHP and 8% pathologists. Of all responders, 50% were female, mainly practicing in public hospital settings (57%) in an urban location (80%) and with an 18-60 years plus age range. The majority of respondents saw the relative advantage of aligning GT to abnormal universal tumour screening (UTS) results, with 77% of GHP and 78% of OHP agreeing it would streamline care for patients. There was disagreement across healthcare professional groups about knowledge and self-efficacy, with 45% of GHP not viewing oncologists as 'feeling confident' to use genetic test results for treatment management decisions, while 62% of OHP felt confident in their ability. Both OHP and GHP's indicated embedding a genetic counsellor in oncology or having a genetics point of contact to support integrating of GT through UTS as favourable interventions. Implementation research findings allow for the design of targeted interventions and a model for GT integration into oncology. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation.ispartof | Eur J Hum Genet | |
dc.relation.isbasedon | 10.1038/s41431-021-00871-4 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 0604 Genetics, 1103 Clinical Sciences | |
dc.subject.classification | Genetics & Heredity | |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Attitude | |
dc.subject.mesh | Colorectal Neoplasms | |
dc.subject.mesh | Endometrial Neoplasms | |
dc.subject.mesh | Female | |
dc.subject.mesh | Genetic Testing | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Mass Screening | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Stakeholder Participation | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Colorectal Neoplasms | |
dc.subject.mesh | Endometrial Neoplasms | |
dc.subject.mesh | Mass Screening | |
dc.subject.mesh | Attitude | |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Female | |
dc.subject.mesh | Male | |
dc.subject.mesh | Genetic Testing | |
dc.subject.mesh | Stakeholder Participation | |
dc.title | Stakeholders' views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology. | |
dc.type | Journal Article | |
utslib.citation.volume | 29 | |
utslib.location.activity | England | |
utslib.for | 0604 Genetics | |
utslib.for | 1103 Clinical Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Genetic Counselling | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2022-06-15T23:29:32Z | |
pubs.issue | 11 | |
pubs.publication-status | Published | |
pubs.volume | 29 | |
utslib.citation.issue | 11 |
Abstract:
Mainstream genetic testing in routine oncology care requires implementation research to inform intervention design. In Australia, funding is available for oncology health professionals (OHP) to organise genetic testing (GT) for eligible colorectal and endometrial cancer patients as part of their routine care. To assess the health system ability to incorporate this practice change, we conducted an implementation survey using the Consolidated Framework for Implementation Research (CFIR). The online survey was available from April to September 2020 to OHP and genetic health professional (GHP). In total, 198 respondents attempted the survey, with 158 completed and 27 partial responses: 26% were GHP, 66% OHP and 8% pathologists. Of all responders, 50% were female, mainly practicing in public hospital settings (57%) in an urban location (80%) and with an 18-60 years plus age range. The majority of respondents saw the relative advantage of aligning GT to abnormal universal tumour screening (UTS) results, with 77% of GHP and 78% of OHP agreeing it would streamline care for patients. There was disagreement across healthcare professional groups about knowledge and self-efficacy, with 45% of GHP not viewing oncologists as 'feeling confident' to use genetic test results for treatment management decisions, while 62% of OHP felt confident in their ability. Both OHP and GHP's indicated embedding a genetic counsellor in oncology or having a genetics point of contact to support integrating of GT through UTS as favourable interventions. Implementation research findings allow for the design of targeted interventions and a model for GT integration into oncology.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph